Antimicrobial drug pathogen list
On March 5, FDA's Anti-Infective Drugs Advisory Committee will discuss important pathogens list for antimicrobial drug development and how preclinical and clinical data from one disease may support approval of antimicrobial drugs in a separate disease. Industry urged development of a list at a meeting on encouraging antibiotic development (1"The Pink Sheet" Nov. 25, 2002, p. 18). [To 2sign up for a webcast or video of this or other advisory committee meetings, visit FDAAdvisoryCommittee.com]...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.